Real-world Alzheimer's disease drug treatment-18-month results from an observational study in three European countries (GERAS; encore from 2016 EAN)

被引：0
|
作者：
Ueda, K. [1 ]
Reed, C. [2 ]
Lebrec, J. [3 ]
Dell'Agnello, G. [4 ]
机构：
[1] Eli Lilly Japan, LRL MDU Japan, Kobe, Hyogo, Japan
[2] Eli Lilly & Co Ltd, GPORWE Biomed, Windlesham, Surrey, England
[3] Eli Lilly & Co, EU Stat, Bad Homburg, Germany
[4] Eli Lilly Italia SpA, Biomed NS Med, Sesto Fiorentino, FI, Italy
来源：
JOURNAL OF THE NEUROLOGICAL SCIENCES | 2017年 / 381卷
关键词：
D O I：
10.1016/j.jns.2017.08.2896
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
2865
引用
收藏
页码：1026 / 1026
页数：1
相关论文
共 50 条
  • [1] Real-world Alzheimer's disease drug treatment-18-month results from an observational study in three European countries (GERAS)
    Reed, C.
    Lebrec, J.
    Dell'agnello, G.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 249 - 249
  • [2] Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study
    Reed, Catherine
    Belger, Mark
    Dell'Agnello, Grazia
    Kahle-Wrobleski, Kristin
    Sethuraman, Gopalan
    Hake, Ann
    Raskin, Joel
    Henley, David
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2018, 10
  • [3] Representativeness of European clinical trial populations in mild Alzheimer’s disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study
    Catherine Reed
    Mark Belger
    Grazia Dell’Agnello
    Kristin Kahle-Wrobleski
    Gopalan Sethuraman
    Ann Hake
    Joel Raskin
    David Henley
    [J]. Alzheimer's Research & Therapy, 10
  • [4] COMPARING RESOURCE USE IN ALZHEIMER'S DISEASE ACROSS THREE EUROPEAN COUNTRIES-18-MONTH RESULTS OF THE GERAS STUDY
    Belger, M.
    Arigmon, J. M.
    Dodel, R.
    Haro, J. M.
    Wimo, A.
    Reed, C.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A759 - A760
  • [5] Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study
    Rapp, Thomas
    Andrieu, Sandrine
    Chartier, Florence
    Deberdt, Walter
    Reed, Catherine
    Belger, Mark
    Vellas, Bruno
    [J]. VALUE IN HEALTH, 2018, 21 (03) : 295 - 303
  • [6] HEALTH STATE VALUES IN ALZHEIMER'S DISEASE - BASELINE RESULTS FROM A LARGE PROSPECTIVE OBSERVATIONAL STUDY IN THREE EUROPEAN COUNTRIES (GERAS)
    Reed, C.
    Argimon, J.
    Belger, M. A.
    Bruno, G.
    Dodel, R.
    Happich, M.
    Haro, J. M.
    Jones, R. W.
    Vellas, B.
    Wimo, A.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A554 - A554
  • [7] OBSERVATIONAL STUDY OF RESOURCE USE AND COST OF ALZHEIMER'S DISEASE IN EUROPE (GERAS)-18-MONTH RESULTS FROM THE FRENCH COHORT
    Rapp, T.
    Vellas, B.
    Andrieu, S.
    Chartier, F.
    Baraille, L.
    Belger, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A409 - A409
  • [8] Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study
    Kahle-Wrobleski, K.
    Andrews, J. S.
    Belger, M.
    Ye, W.
    Gauthier, S.
    Rentz, D. M.
    Galasko, D.
    [J]. JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE, 2017, 4 (02): : 72 - 80
  • [9] Assessing the Progression of Alzheimer's Disease in Real-World Settings in Three European Countries
    Llado, Albert
    Froelich, Lutz
    Khandker, Rezaul K.
    Roset, Montserrat
    Black, Christopher M.
    Lara, Nuria
    Chekani, Farid
    Ambegaonkar, Baishali M.
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2021, 80 (02) : 749 - 759
  • [10] Costs associated with Alzheimer's disease in Italy: baseline results from the GERAS II observational study
    Bruti, G.
    Bruno, G.
    Mancini, M.
    Reed, C.
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2016, 52 : S61 - S62
12345